Is PLXS a Buy? What to Consider in 2026
Last updated July 2026
Short answer
The bull case for Plexus Corp (PLXS) rests on Regulated-market specialization: Plexus concentrates on aerospace/defense, healthcare/life sciences, and industrial customers where strict regulatory and quality requirements create high switching costs. Revenue (TTM) is ~$4.1B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The most cited risk is valuation: the stock has roughly doubled in a year and trades at a premium price-to-earnings multiple, creating meaningful downside if growth or margins disappoint. Whether PLXS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Plexus Corp (NASDAQ: PLXS), headquartered in Neenah, Wisconsin and operating since 1979, is a contract electronics manufacturer that provides integrated lifecycle solutions spanning design and development, supply chain, new product introduction, manufacturing, and aftermarket services. Unlike the scale-driven giants of the EMS industry, Plexus deliberately targets mid-to-low volume, higher-complexity programs in three regulated sectors: Aerospace/Defense, Healthcare/Life Sciences, and Industrial. Its work includes life-saving medical devices, mission-critical defense electronics, industrial automation, and semiconductor capital equipment, where certifications, traceability, and engineering rigor matter more than raw volume economics. The investment picture is one of a high-quality niche operator that the market has recently embraced. Fiscal 2026 has featured record revenue and expanding margins, with the stock roughly doubling over twelve months as investors reassessed the structural role EMS players hold in modern supply chains. That enthusiasm has pushed the valuation to a premium relative to Plexus's own history. Bulls point to durable demand in defense and medical and to margin discipline, while skeptics note that the multiple has expanded faster than earnings and that Plexus's exposure to the AI infrastructure theme is indirect.
What's the case for buying PLXS?
1. Regulated-market specialization
Plexus concentrates on aerospace/defense, healthcare/life sciences, and industrial customers where strict regulatory and quality requirements create high switching costs. This focus tends to support steadier margins and stickier programs than commodity high-volume manufacturing. It also gives Plexus pricing leverage that pure scale players struggle to match.
2. Program ramps and revenue momentum
Recent quarters have shown strong year-over-year revenue growth driven by ramping programs across all three sectors, including industrial semiconductor capital equipment and defense. Fiscal Q2 2026 delivered record revenue of roughly $1.16 billion, up around 19% year over year. Continued program wins and ramps are the primary near-term growth driver.
3. Margin expansion and mix
Management has emphasized improving operating margins as higher-complexity, higher-value work grows as a share of the mix. Non-GAAP operating margin reached about 6.0% in fiscal Q2 2026. Sustained mix improvement toward premium programs is central to the earnings-growth story.
4. Supply-chain and reshoring tailwinds
Structural interest in resilient, diversified, and regionalized manufacturing supply chains has increased demand for capable EMS partners. Plexus's global footprint across the Americas, EMEA, and Asia-Pacific positions it to serve customers seeking flexibility. Broader AI-infrastructure and industrial-electronics spending indirectly supports order flow.
What are the risks to PLXS?
The most cited risk is valuation: the stock has roughly doubled in a year and trades at a premium price-to-earnings multiple, creating meaningful downside if growth or margins disappoint. EMS is cyclical and demand can soften quickly if end-market customers cut orders or push out programs. Plexus depends on a relatively concentrated set of large customers, so the loss or slowdown of a major program can materially affect results. Tariffs, trade disputes, and shifting trade policy add cost and complexity to a globally distributed manufacturing base. Finally, Plexus's AI exposure is indirect, which could limit upside relative to peers with more direct data-center content while still leaving it exposed to any broad tech-spending pullback.
How is PLXS valued? (as of July 2026)
Snapshot for PLXS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$4.1B
- Net income (TTM): ~$173M
- Fiscal Q2 2026 revenue: ~$1.16B (record)
- Fiscal Q2 2026 non-GAAP EPS: ~$2.05
- Market cap: ~$7B
- P/E (TTM): ~34x to 38x
Plexus generates roughly $4.1 billion in trailing revenue and around $173 million in net income, with fiscal Q2 2026 setting a quarterly revenue record near $1.16 billion. The stock has roughly doubled over the prior year, lifting its trailing P/E into the mid-to-high 30s and its forward P/E to the high 20s to low 30s. That places it at a premium to its own history and richer than several EMS peers, reflecting optimism about margin expansion that has already been partly priced in.
How do you decide if PLXS is a buy?
Rather than asking whether PLXS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold PLXS indirectly through an index or sector ETF before adding more.
For the full picture, see the PLXS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about PLXS against your real portfolio and see your actual exposure before deciding.
The bottom line on PLXS
The bottom line: Plexus Corp's story right now is Regulated-market specialization, with revenue (ttm) at ~$4.1B. If you believe that narrative continues, the call is about sizing PLXS sensibly and checking overlap with what you own; if you doubt it (the risk: the most cited risk is valuation: the stock has roughly doubled in a year and trades at a premium price-to-earnings multiple, creating meaningful downside if growth or margins disappoint.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around PLXS with Walnut
Use Plexus Corp as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is PLXS a good stock to buy right now?
+
The case for Plexus Corp right now is Regulated-market specialization, with revenue (ttm) at ~$4.1B. If you believe that thesis holds, PLXS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the most cited risk is valuation: the stock has roughly doubled in a year and trades at a premium price-to-earnings multiple, creating meaningful downside if growth or margins disappoint. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Plexus Corp do?
+
Plexus Corp (NASDAQ: PLXS), headquartered in Neenah, Wisconsin and operating since 1979, is a contract electronics manufacturer that provides integrated lifecycle solutions spannin
What are the main risks of PLXS?
+
The most cited risk is valuation: the stock has roughly doubled in a year and trades at a premium price-to-earnings multiple, creating meaningful downside if growth or margins disappoint. EMS is cyclical and demand can soften quickly if end-market customers cut orders or push out programs. Plexus depends on a relatively concentrated set of large customers, so the loss or slowdown of a major program can materially affect results. Tariffs, trade disputes, and shifting trade policy add cost and complexity to a globally distributed manufacturing base. Finally, Plexus's AI exposure is indirect, which could limit upside relative to peers with more direct data-center content while still leaving it exposed to any broad tech-spending pullback.
What does Plexus Corp do?
+
Plexus is an electronics manufacturing services (EMS) company. It designs, manufactures, and services highly complex electronic products for customers in aerospace/defense, healthcare/life sciences, and industrial markets, handling everything from design and supply chain to manufacturing and aftermarket support.
What makes Plexus different from Jabil or Flex?
+
Jabil and Flex are far larger and focus on high-volume manufacturing, each generating well over $25 billion in revenue. Plexus is much smaller at around $4 billion and specializes in mid-to-low volume, high-complexity programs in regulated industries where certifications and traceability matter more than scale.
Is Plexus profitable?
+
Yes. Plexus is consistently profitable, with trailing twelve-month net income of roughly $173 million on about $4.1 billion of revenue. Fiscal Q2 2026 delivered record revenue and a non-GAAP operating margin near 6.0%.
Why has PLXS stock risen so much?
+
The stock roughly doubled over the past year as investors re-rated EMS companies for their structural role in supply chains, and as Plexus posted record revenue and margin expansion. The enthusiasm has pushed its valuation to a premium relative to its own history.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell PLXS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.